Fulgent Genetics Company Insiders

FLGT Stock  USD 16.96  0.67  3.80%   
Fulgent Genetics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Fulgent Genetics stock suggests that vertually all insiders are panicking at this time. Fulgent Genetics employs about 1.2 K people. The company is managed by 12 executives with a total tenure of roughly 9 years, averaging almost 0.0 years of service per executive, having 98.67 employees per reported executive.
Ming Hsieh  Chairman
Chairman of the Board and Presidentident, CEO

Fulgent Genetics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-25Ming HsiehDisposed 2227 @ 18.26View
2024-08-27Paul KimDisposed 733 @ 22.83View
Monitoring Fulgent Genetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Fulgent Genetics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Fulgent Genetics' future performance. Based on our forecasts, it is anticipated that Fulgent will maintain a workforce of slightly above 1180 employees by February 2025.
 
Covid

Fulgent Genetics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2025. Return On Capital Employed is likely to drop to -0.06 in 2025. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 35 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2025.
Common Stock Shares Outstanding is likely to drop to about 23.5 M in 2025. Net Income Applicable To Common Shares is likely to drop to about 101.5 M in 2025

Fulgent Genetics Workforce Comparison

Fulgent Genetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 269,691. Fulgent Genetics adds roughly 1,184 in number of employees claiming only tiny portion of equities under Health Care industry.

Fulgent Genetics Profit Margins

The company has Profit Margin (PM) of (0.59) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.24.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.440.33
Significantly Up
Slightly volatile

Fulgent Genetics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulgent Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulgent Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fulgent Genetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.25
4
16
 25,481 
 23,481 
2024-03-01
0.5
13
26
 1,200,596 
 1,069,039 
2023-09-01
0.0714
1
14
 750,000 
 780,843 
2023-06-01
0.3636
4
11
 17,727 
 14,681 
2023-03-01
0.6471
11
17
 126,382 
 26,304 
2022-12-01
0.6
6
10
 1,266,420 
 13,071 
2022-09-01
0.7778
7
9
 855,200 
 13,416 
2022-06-01
0.4118
7
17
 2,006,626 
 23,664 
2022-03-01
0.5625
9
16
 124,875 
 16,513 
2021-09-01
0.2857
4
14
 750,936 
 35,397 
2021-06-01
0.4375
7
16
 14,376 
 40,037 
2021-03-01
0.1818
2
11
 3,124 
 75,026 
2020-12-01
0.0435
1
23
 2,631 
 210,743 
2020-09-01
0.2143
3
14
 242,631 
 766,393 
2020-06-01
0.6667
4
6
 15,131 
 541,969 
2019-12-01
1.0
1
1
 40,000 
 1,326 
2019-09-01
1.0
3
3
 50,000 
 512,389 
2019-06-01
2.0
2
1
 10,000 
 1,404 
2019-03-01
2.0
2
1
 28,739 
 1,165 
2018-12-01
2.0
2
1
 20,880 
 1,446 
2018-06-01
2.0
2
1
 10,000 
 1,370 
2017-12-01
10.0
10
1
 55,763 
 1,573 
2016-09-01
0.5882
10
17
 12,980,328 
 65,922,106 
2016-06-01
1.5
3
2
 40,001 
 7,184,210 

Fulgent Genetics Notable Stakeholders

A Fulgent Genetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fulgent Genetics often face trade-offs trying to please all of them. Fulgent Genetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fulgent Genetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ming HsiehChairman of the Board and Presidentident, CEOProfile
Ray YinPresident PharmaProfile
Jian XieCOO PresidentProfile
Doreen NgVP OfficeProfile
DABMG FACMGChief DirectorProfile
Paul KimChief OfficerProfile
Natalie PrescottGeneral OfficerProfile
Lawrence MDChief OfficerProfile
Brandon PerthuisChief OfficerProfile
Ellen TsuiVice ResourcesProfile
Jakub SramVice SalesProfile
Paul CPAChief OfficerProfile

About Fulgent Genetics Management Performance

The success or failure of an entity such as Fulgent Genetics often depends on how effective the management is. Fulgent Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fulgent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fulgent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.14)(0.15)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.12)(0.13)
Return On Equity(0.13)(0.14)
Please note, the imprecision that can be found in Fulgent Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fulgent Genetics. Check Fulgent Genetics' Beneish M Score to see the likelihood of Fulgent Genetics' management manipulating its earnings.

Fulgent Genetics Workforce Analysis

Traditionally, organizations such as Fulgent Genetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fulgent Genetics within its industry.

Fulgent Genetics Manpower Efficiency

Return on Fulgent Genetics Manpower

Revenue Per Employee244.3K
Revenue Per Executive24.1M
Net Loss Per Employee141.7K
Net Loss Per Executive14M
Working Capital Per Employee367.3K
Working Capital Per Executive36.2M

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.